The HR/PARP synthetic lethality model may be more widely applicable in prostate cancer with germline or somatic inactivating mutations in the HR DNA repair genes, CHK2, BRIPI/FANCJ, NBS1, BRCA1, and ATM, collectively thought to occur in 20–25% of prostate cancer cases. The gene discussed is CHEK2; the disease is prostate carcinoma.